Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome.
Tegaserod is a selective partial agonist acting on serotonergic type 4 receptors (5-HT(4)). Pharmacodynamic studies indicate that tegaserod is able to stimulate gut propulsion and secretion with a net prokinetic effect. In contrast to other 5-HT(4) agonists endowed with a complex pharmacological profile, tegaserod has a reliable prokinetic activity in the colon. Clinical trials show that tegaserod is effective and safe in the treatment of patients with irritable bowel syndrome. In particular, tegaserod relieves symptoms of abdominal pain, discomfort, abdominal bloating and constipation.
Corsetti
Maura
M
Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, University of Leuven, Belgium.
Tack
Jan
J
D000818:Animals; D001682:Biological Availability; D002986:Clinical Trials as Topic; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D007211:Indoles / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D007408:Intestinal Absorption; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D014018:Tissue Distribution
D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod